NL-OMON56725尚未招募不适用
In-house dual CAR T-cell therapy development - ID-CAR T trial
Amsterdam UMC0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •18 years and older
- •Be able to read, understand and give informed consent
- •Have MM and belong to 1 of the following subgroups:
- •Group 1A: MM patients, triple refractory
- •Group 2A: MM patients, treated with BsAbs, either on treatment or within 3
- •months after discontinuation
- •Group 1B: MM patients having received first line treatment only
- •Group 1C: Newly diagnosed MM patients
- •Group 2B: MM patients > 3 months after BsAbs treatment discontinuation
- •For the full scale experiment: the haemoglobin level should be > 6.5 mmol/L,
- •lower haemoglobin levels (5,0-6,5 mmol/L) are accepted when blood withdrawal is
- •combined with an already scheduled routine blood transfusion.
排除标准
- •not being able to give informed consent
- •A lymphocyte count of < 0.5 x 10^9/L
- •Use of corticosteroids > 20 mg a day in the 7 days before blood withdrawal.
- •The same counts for any other immunosuppressant drug
- •Haemoglobin level < 5,0 mmol/L
- •For the full scale experiment: any condition which may possibly interfere
- •with the safety of extra blood withdrawal.
研究者
相似试验
招募中
1 期
Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic LeukemiaB-cell Acute Lymphoblastic LeukemiaNCT05210907Seoul National University Hospital5
招募中
1 期
Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) PatientsCAR-T Cell TherapyNCT05858684RenJi Hospital18
进行中（未招募）
1 期
DK-CLIC-1901 CAR T-cells for treatment of patients with relapsed/refractory CD19 positive hematological malignancies (DAN-CART 1901)CTIS2024-515174-27-00Rigshospitalet20
招募中
不适用
Tissue Study in Patients Undergoing CAR-T Cell Therapy (CAR_21_01)CAR-T Therapy ComplicationsNCT04892433IRCCS Azienda Ospedaliero-Universitaria di Bologna150
Unknown
早期 1 期
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT04626752Hebei Senlang Biotechnology Inc., Ltd.50